Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

@article{Meer2009PioglitazoneIC,
  title={Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.},
  author={Rutger W. van der Meer and Luuk J. Rijzewijk and H W de Jong and Hildo J. Lamb and Mark Lubberink and Johannes Anthonius Romijn and Jeroen J. Bax and Albert de Roos and Otto Kamp and Walter Paulus and R. Heine and Adriaan A. Lammertsma and Jan Smit and Michaela Diamant},
  journal={Circulation},
  year={2009},
  volume={119 15},
  pages={2069-77}
}
BACKGROUND Cardiac disease is the leading cause of mortality in type 2 diabetes mellitus (T2DM). Pioglitazone has been associated with improved cardiac outcome but also with an elevated risk of heart failure. We determined the effects of pioglitazone on myocardial function in relation to cardiac high-energy phosphate, glucose, and fatty acid metabolism and triglyceride content in T2DM patients. METHODS AND RESULTS Seventy-eight T2DM men without structural heart disease or inducible ischemia… CONTINUE READING